Emergent BioSolutions, Inc., recently signed a license agreement for the manufacture and sale of VaxInnate Corporation’s recombinant influenza vaccine.
The deal is considered to be a step in the right direction towards preparing the United States for the event of a major influenza pandemic. The licensing agreement grants Emergent BioSolutions, Inc., the right to manufacture and sell VaxInnate’s pandemic flu vaccine in the United States. VaxInnate, in turn, will receive payments and royalties associated with vaccine’s production and sale.